Lung Cancer and Nodule Care: questions and answers

In detail

Pulmonary nodules are areas of abnormal growth seen on chest X-rays or CT scans. Most are benign, caused by infections, inflammation, scarring or inhaled particles, but some represent early cancer.

The team assesses nodule size, shape and density — solid, ground-glass or part-solid — and your risk factors such as smoking history.

For suspicious nodules larger than 9 millimetres or those with concerning features, the tumour board guides the next step, which may be CT-guided percutaneous biopsy for peripheral nodules or EBUS and EUS for mediastinal nodal staging.

Molecular testing such as EGFR, ALK and ROS1 is arranged when cancer is confirmed to guide targeted therapy or immunotherapy decisions.

In detail

Small lung nodules rarely cause symptoms. When a growth presses on the airway or is cancerous, symptoms such as cough, haemoptysis, weight loss, breathlessness, chest pain, hoarseness, or recurrent infections can appear.

Risk factors like smoking history, occupational exposure, or family history increase the likelihood that a nodule is malignant.

The team uses these clinical clues along with imaging features — size over 9 millimetres, irregular edges, or growth on serial scans — to decide on biopsy or surveillance.

In detail

While routine nodules and early cancer are managed in the OPD, certain complications require immediate attention. Coughing up more than a few teaspoons of blood can signal airway bleeding that may worsen quickly.

Sudden breathlessness may mean a blocked airway, pleural effusion or a blood clot in the lung. Severe crushing chest pain could be a heart attack, which is more common in patients with cancer or after certain treatments.

The hospital's emergency department, ICU and ambulance service are available round the clock for these situations. Do not wait for a scheduled appointment if any of these warning signs appear.

In detail

The doctor starts by taking a detailed history including smoking, occupational exposure, and family history. They review prior chest X-rays or CT scans where nodules appear as spots different from normal lung tissue. Nodules may be described as solid, ground-glass opacity, or part-solid.

The doctor explains that a CT scan alone cannot confirm cancer; only a biopsy can. Features like size under 6 millimetres or smooth edges suggest lower risk. Based on this, the doctor may order a PET-CT, CT-guided biopsy, EBUS, or blood tests. Complex cases go to the tumour board where pulmonologists, oncologists, surgeons, radiologists, and pathologists review together.

In detail

Guidelines suggest nodules smaller than 6 millimetres with smooth edges are usually less likely cancerous. A biopsy is likely recommended if a nodule exceeds 9 millimetres or you have risk factors. The doctor considers whether the nodule is solid, ground-glass, or part-solid.

PET-CT helps assess metabolic activity and distant spread. For tissue diagnosis, options include CT-guided percutaneous biopsy for peripheral nodules, EBUS or EUS for mediastinal nodes, or surgical biopsy.

Molecular testing for EGFR, ALK, ROS1, and PD-L1 is standard for advanced non-small cell lung cancer to guide targeted therapy or immunotherapy. The tumour board reviews complex cases.

In detail

If the nodule is benign or very low risk, the tumour board recommends a schedule of follow-up CT scans — typically at six to twelve months — and stops if the nodule is stable for two years.

If cancer is confirmed, the stage (early, locally advanced or metastatic) decides the modality: surgery for early stage, combined chemoradiation for locally advanced, and systemic therapy for stage four.

Molecular profiling is critical: EGFR mutations qualify you for oral osimertinib; ALK or ROS1 rearrangements for specific inhibitors; high PD-L1 expression may favour pembrolizumab immunotherapy. The multidisciplinary board reviews every result together to sequence treatments correctly and avoid ineffective chemotherapy when a targeted option exists. Waiting for molecular results before starting systemic therapy is standard practice.

In detail

The multidisciplinary tumour board tailors the plan. Surgery for early non-small cell lung cancer typically involves a 4 to 7 night stay and 4 to 6 weeks recovery. Radiation courses last 6 to 8 weeks as an outpatient.

Systemic therapy — chemotherapy, immunotherapy like nivolumab or pembrolizumab, or oral targeted drugs like osimertinib for EGFR mutations — runs in cycles over 3 to 6 months.

Molecular testing guides the choice: EGFR mutations favour osimertinib; ALK or ROS1 rearrangements have specific inhibitors; high PD-L1 may lead to pembrolizumab.

In studies, osimertinib showed median progression-free survival of 18.9 months versus 10.2 months with older EGFR drugs, and nivolumab improved overall survival compared to docetaxel. The full treatment course typically ranges from ₹1,50,000 to ₹15,00,000 depending on the regimen.

In detail

Guidelines recommend active surveillance for nodules under 6 millimetres or those with benign features — follow-up CT at six to twelve months, stopping after two years of stability. If an infection causes the nodule, a course of antibiotics or antifungals resolves it.

For patients undergoing surgery, prehabilitation with breathing exercises and nutritional optimisation shortens recovery. After surgery or during chemotherapy and immunotherapy, pulmonary rehabilitation improves exercise tolerance and quality of life.

Smoking cessation is the single most effective lifestyle change; it lowers recurrence risk and improves treatment tolerance. The team at Jaipur Hospital integrates these non-surgical measures into every care plan alongside the primary treatment.

In detail

Evidence shows that nodules larger than 9 millimetres, those with irregular edges, or those that grow over time are more likely to be cancerous and may need a biopsy. If cancer is confirmed, surgery is usually the preferred option for early-stage non-small cell lung cancer.

For advanced disease, systemic therapy such as chemotherapy, targeted therapy, or immunotherapy is chosen based on molecular testing. The tumour board, including a pulmonologist, oncologist, thoracic surgeon, radiologist, and pathologist, discusses each case to decide the right approach.

In detail

Evidence from clinical studies shows varied response patterns. For immunotherapy such as nivolumab or pembrolizumab, overall survival benefit emerges over months; median overall survival was 12.2 months with nivolumab versus 9.4 months with docetaxel in one study.

Targeted therapy with osimertinib showed median progression-free survival of 18.9 months. Chemotherapy responses are typically assessed after two to three cycles. Radiation-related symptom relief such as reduced cough or breathlessness often begins during or shortly after the six to eight week course.

Each modality has its own trajectory, and the tumour board tailors the plan to your cancer stage, mutation profile, and overall health.

In detail

Evidence shows treatment-related adverse events of grade 3 or 4 occurred in 10 percent of patients receiving nivolumab and 54 percent receiving docetaxel. Immunotherapy can cause immune-related inflammation in the lungs, liver, or endocrine glands. Chemotherapy often lowers blood counts, raising infection risk.

Radiation may cause oesophagitis or pneumonitis weeks after completion. The multidisciplinary team monitors for these complications. Early reporting allows dose adjustment, supportive medication, or hospital admission if required. Your oncologist and pulmonologist coordinate care through the tumour board.

In detail

Evidence indicates treatment-related fatigue is common across modalities. Surgery patients need four to seven nights in hospital and gradual return to normal activity over four to six weeks.

Chemotherapy cycles every two to three weeks can lower haemoglobin and white cells, increasing infection risk during travel. Immunotherapy side effects such as pneumonitis or colitis may appear unpredictably. Radiation to the chest can cause temporary oesophagitis, affecting eating.

International travel is usually discouraged during active systemic therapy due to infection risk and need for regular blood monitoring. The tumour board considers performance status when planning treatment, and the physiotherapy department supports graded exercise recovery.

In detail

Evidence shows non-small cell lung cancer includes adenocarcinoma, squamous cell, and large cell types. Molecular testing for EGFR, ALK, ROS1 mutations guides targeted therapy. Small cell lung cancer is staged as limited or extensive. Grade ranges from well-differentiated to poorly differentiated.

Stage uses the TNM system: T for tumour size and invasion, N for lymph node involvement, M for distant metastasis. Stages I to III are potentially curable with surgery, radiation, or combined modality. Stage IV indicates metastatic disease treated with systemic therapy.

Next-generation sequencing identifies mutations that determine eligibility for oral targeted drugs or immunotherapy. The multidisciplinary team correlates pathology, imaging, and molecular results to assign accurate stage and select therapy.

In detail

Evidence supports a stepwise approach. CT chest and upper abdomen evaluate the primary tumour, lymph nodes, liver, and adrenal glands. PET-CT detects metabolically active disease elsewhere. Brain MRI is recommended because lung cancer frequently metastasises to the brain.

EBUS or EUS-guided staging provides minimally invasive mediastinal nodal sampling with high accuracy. For peripheral nodules, CT-guided percutaneous biopsy obtains tissue. Molecular testing on biopsy tissue includes EGFR, ALK, ROS1, and broader next-generation sequencing panels.

The multidisciplinary tumour board — pulmonologist, oncologist, thoracic surgeon, radiologist, pathologist — correlates all results to confirm stage and guide treatment. Staging directly determines whether surgery, radiation, or systemic therapy is appropriate.

In detail

This team approach ensures that surgery, radiation, chemotherapy, targeted therapy, and immunotherapy are all considered from the start. The pulmonologist assesses lung function and biopsy options. The surgeon evaluates resectability.

The oncologist selects systemic therapy based on stage and mutations such as EGFR, ALK, ROS1, and PD-L1. The radiologist and pathologist confirm staging and diagnosis. This joint review reduces the chance of missed options and aligns the plan with current guidelines.

In detail

A multidisciplinary tumour board reviews each case. For early non-small cell lung cancer, surgery is the preferred treatment option to remove the tumour. For advanced stages, systemic therapy such as chemotherapy, targeted therapy or immunotherapy is used to slow progression.

Evidence shows pembrolizumab improves progression-free survival compared with chemotherapy alone in certain patients. Osimertinib provides longer progression-free survival than standard EGFR inhibitors for EGFR-mutated disease. Nivolumab improves overall survival compared with docetaxel in previously treated patients.

For benign nodules, active surveillance with repeat imaging at six to twelve months is standard. If a nodule grows or causes symptoms, biopsy or surgery may be needed.

In detail

The choice depends on stage, molecular profile, and fitness. For stage I-II non-small cell lung cancer, surgery offers the highest chance of long-term control; lobectomy is standard, with sublobar resection for select patients. In studies, adjuvant chemotherapy after resection improves survival in higher-risk early stages.

For unresectable stage III, concurrent chemoradiation is standard. For stage IV, treatment is guided by biomarkers: EGFR, ALK, ROS1 mutations direct targeted therapy; high PD-L1 may favour immunotherapy. Evidence shows osimertinib gives longer progression-free survival than older EGFR inhibitors.

Pembrolizumab plus chemotherapy improves overall survival versus chemotherapy alone in metastatic non-squamous disease. For small nodules under 6 mm with smooth edges, guidelines recommend CT surveillance at six to twelve months because most are benign. EBUS or CT-guided biopsy confirms diagnosis before treatment. The tumour board matches the modality to your disease and health.

In detail

Most pulmonary nodules are benign. Radiologists see nodules in nearly one in three chest CT scans. Features that raise concern include size above 9 mm, spiculated or irregular margins, part-solid or ground-glass appearance, and growth on serial imaging.

Risk factors include age over 50, current or former smoking, occupational exposure to asbestos or silica, and prior malignancy. Guidelines suggest that nodules under 6 mm with low-risk features usually need no immediate action; a follow-up CT at twelve months is typical.

Nodules 6 to 8 mm may need a three- to six-month follow-up. Nodules over 8 mm or those with suspicious features often warrant PET-CT or biopsy. EBUS or CT-guided percutaneous biopsy provides tissue diagnosis.

The multidisciplinary tumour board at Jaipur Hospital reviews imaging and risk factors to recommend observation, further imaging, or biopsy. Early evaluation avoids unnecessary procedures for benign nodules while catching cancer when it is most treatable.

In detail

Low-dose CT screening reduces lung cancer mortality by detecting tumours at an earlier, more treatable stage. Major trials showed a 20 percent reduction in lung cancer deaths among high-risk smokers screened annually with low-dose CT versus chest X-ray.

The test uses minimal radiation and takes a few minutes. It is not recommended for people outside the high-risk group because false positives can lead to unnecessary anxiety and invasive tests.

Eligibility typically includes age 50 to 80, at least 20 pack-years of smoking, and current smoking or cessation within 15 years. A pack-year equals one pack per day for one year.

If you have symptoms such as persistent cough, haemoptysis, or unexplained weight loss, you need diagnostic CT, not screening. The pulmonologist at Jaipur Hospital will confirm eligibility, explain the benefits and harms, and arrange the scan if appropriate. A positive screen leads to a structured nodule evaluation pathway with the multidisciplinary team.

• Major trials showed a 20 percent reduction in lung cancer deaths among high-risk smokers screened annually with low-dose CT versus chest X-ray.

In detail

Imaging cannot definitively diagnose lung cancer. A tissue sample is needed for histology and molecular testing such as EGFR, ALK, ROS1, and PD-L1, which guide targeted therapy and immunotherapy choices.

Guidelines recommend biopsy for nodules over 9 mm or those with spiculation, growth, or high metabolic activity on PET-CT. EBUS or EUS-guided biopsy samples mediastinal nodes for staging and diagnosis in one procedure. CT-guided percutaneous biopsy targets peripheral nodules.

Surgical biopsy via VATS is used when less invasive methods fail or are unsuitable. Adequate tissue is critical; studies show next-generation sequencing requires sufficient sample to avoid repeat procedures.

The tumour board at Jaipur Hospital selects the safest, highest-yield approach based on lesion location and patient fitness. Molecular results typically take one to two weeks and determine whether you receive a targeted tablet, immunotherapy, or chemotherapy.

In detail

Small lung nodules rarely cause symptoms. However, lung cancer and its treatment can lead to serious complications. Tumour growth may obstruct an airway, causing breathlessness or collapse of lung tissue.

Cancer increases the risk of blood clots in the lungs, presenting as sudden breathlessness and chest pain. Chemotherapy and immunotherapy can cause lung inflammation (pneumonitis), with fever, cough and falling oxygen levels.

Evidence shows grade 3 or 4 treatment-related adverse events occurred in 10 percent of patients on nivolumab and 54 percent on docetaxel. Radiation can cause oesophagitis or pneumonitis weeks after completion. Pleural effusion from cancer or infection causes progressive breathlessness.

Any rapid change in breathing, new chest pain, haemoptysis, or oxygen saturation below 94 percent warrants immediate evaluation in the 24-hour emergency department.

In detail

Tobacco smoking is the leading cause of lung cancer, responsible for the majority of cases. Risk rises with duration and intensity; a 20 pack-year history is a common threshold for screening eligibility. Second-hand smoke also contributes.

Outdoor air pollution, especially fine particulate matter (PM2.5), is a recognised carcinogen. Occupational carcinogens include asbestos, silica, diesel exhaust, arsenic, chromium, nickel, and radon. Asbestos exposure also raises mesothelioma risk.

Prior lung diseases such as tuberculosis, chronic obstructive pulmonary disease, and pulmonary fibrosis create scarring that can appear as nodules and may increase cancer risk. Certain autoimmune conditions and chronic infections cause inflammatory nodules.

The multidisciplinary team at Jaipur Hospital asks about smoking history, occupation, residential area, and past lung illnesses to assess your risk profile. This history helps decide whether a nodule needs biopsy or surveillance, and whether you qualify for low-dose CT screening. Quitting smoking at any stage reduces future risk and improves treatment tolerance.

In detail

Costs vary widely because treatment is highly individualised. Early-stage surgery alone costs less than multi-modality therapy for advanced disease. A lobectomy with a four- to seven-night stay forms the surgical base cost.

Chemotherapy cycles run every two to three weeks for three to six months; drug costs differ between generic platinum doublets and newer agents. Targeted therapies such as osimertinib or immunotherapy such as pembrolizumab are more expensive per cycle but may be given for longer periods.

Radiation therapy over six to eight weeks adds facility and planning charges. Molecular testing (EGFR, ALK, ROS1, PD-L1, NGS) is an upfront cost that guides drug selection and avoids ineffective treatment. Studies note that total expenses depend on mutation profile and drug choice.

The hospital accepts RGHS, MAA Yojana, CGHS, and private insurance TPAs, which can reduce out-of-pocket expenditure. The billing team provides an itemised estimate after the tumour board finalises the plan.

In detail

The wide range reflects the variety of treatment pathways. Early-stage disease may need only surgery with a 4 to 7 night stay, while advanced disease often requires multiple chemotherapy or immunotherapy cycles over 3 to 6 months.

Our usual protocols note that targeted therapy and immunotherapy are guided by EGFR, ALK, ROS1 testing, and these specialised drugs add significant cost.

Evidence from Indian oncology centres shows that next-generation sequencing is essential before starting systemic therapy, and drug choice depends on the mutation profile. The multidisciplinary tumour board reviews each case to decide the plan, which determines the final cost structure.